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Summary
Background: Spironolactone was shown to reduce mortality in patients with heart failure (HF).
However, the effect of spironolactone on the incidence of atrial ﬁbrillation remains unknown.
Therefore, we examined the effects of spironolactone on atrial conduction and remodeling in
patients with HF.
Methods and results: A total of 21 patients with HF were divided into either spironolactone
group (n = 11) or control group (n = 10). The patients were followed up for 12 months. Blood
examination, echocardiogram, and signal-averaged electrocardiogram were performed at study
enrollment and after 3 and 12 months of treatment. In the spironolactone group, atrial natri-
uretic peptide tended to reduce, left atrium dimension was signiﬁcantly smaller, the ratio of E
wave to A wave tended to improve, and P-duration was signiﬁcantly shortened.
e imp
f CarConclusions: Spironolacton
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ntroductiontrial ﬁbrillation (AF) in patients with heart failure
HF) is generally considered a negative prognostic fac-
or. Several studies have shown that activation of the
enin—angiotensin—aldosterone system is associated with
Published by Elsevier Ltd. All rights reserved.
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the mechanism of AF [1—3]. Angiotensin-converting enzyme
(ACE) inhibitors and the angiotensin II type 1 (AT1) recep-
tor antagonists have been shown to be effective in reducing
the incidence of AF in addition to the rate of mortality in
patients with HF [3—6]. However, the rate of AF in patients
with HF remains relatively high despite the success achieved
with ACE inhibitors and AT1 receptor antagonists in the
treatment of AF. This high rate is partly due to the aldos-
terone (ALD) escape phenomenon [7—10].
ALD has an important role in the pathophysiology of
HF [11—14]. In the Randomized Aldactone Evaluation Study
(RALES), the mineralocorticoid receptor antagonist spirono-
lactone was shown to reduce mortality in patients with
HF, and the beneﬁcial outcome in RALES was shown to be
associated with the suppression of the marker of cardiac col-
lagen synthesis by spironolactone [15]. Moreover, ALD levels
have been found to increase with profound implications for
left ventricular remodeling and long-term prognosis [16,17].
However, the effect of spironolactone on atrial conduction
and remodeling remains unknown.
Therefore, in the present study, we examined the effects
of spironolactone on atrial conduction and remodeling in
patients with HF.
Methods
Patient population
We studied 21 patients with stable symptomatic HF [New
York Heart Association (NYHA) functional class II or III] and
left ventricular ejection fraction (LVEF) <40%. There were
15 men and 6 women (mean age, 68 years). The cause of
HF was dilated cardiomyopathy in 14 patients and ischemic
cardiomyopathy in 7 patients. Patients were excluded if
they had primary operable valvular heart disease, congenital
heart disease, unstable angina, renal failure, hyperkalemia,
primary hepatic failure, or AF. On enrollment in the study, 21
patients were being treated with loop diuretics, 12 with ACE
inhibitors, and 9 with AT1 receptor antagonists. All patients
were being treated with ACE inhibitors or AT1 receptor
antagonists. The antiarrhythmic drug amiodarone was used
for prevention of ventricular tachycardia. Most of these
drugs had been administered for >3 months.
Study protocol
All of the patients were in a stable condition for at least
three months before enrollment. Fig. 1 shows the study pro-
tocol. The 21 patients with mild-to-moderate symptomatic
left ventricular dysfunction were randomly divided into two
groups that received treatment with spironolactone (n = 11)
or no additional drug (n = 10). The dose of spironolactone
was set at 25mg once daily.
The patients were followed up for 12 months. Blood sam-
ples were collected from each patient at study enrollment
and after 3 and 12 months of treatment. To measure the
plasma levels of neurohumoral factors, blood samples were
collected from an antecubital vein following supine rest for
at least 30min. Echocardiogram and signal-averaged elec-
trocardiogram triggered by P waves (P-SAECG) were also
performed at study enrollment and after 3 and 12 months of
(
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ﬁ
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tigure 1 Study protocol. HF, heart failure; P-SAECG, signal-
veraged electrocardiogram triggered by P waves.
reatment. Echocardiogram was performed with a 3.75-MHz
ransducer connected to an ultrasound system (Prosound
SD-4000, Aloka, Tokyo, Japan). The dimension and LVEF
ere determined by M-mode. The peak velocities of early
E) and late (A) mitral inﬂow were measured using pulse-
ave Doppler with the sample volume at the tip of mitral
alve leaﬂets.
ignal-averaged electrocardiogram triggered by P
aves
-SAECG was recorded using the MAC-5000 (GE Medical Sys-
ems, USA). This system uses P-wave for both triggering and
atching with a template. Data are acquired for P-SAECG
rom the surface ECG in three mutually perpendicular axes
f the Frank lead system. The X lead is from left to right mid
xillary line at the ﬁfth intercostal space. The Y lead is from
ead to foot, and the Z lead is from the sternum at ﬁfth
ntercostal space to directly posterior. Signals were then
mpliﬁed and digitized at a sampling rate of 1000 samples/s
nd a resolution of 1V.
A P-wave template was initially generated for P-wave
atching using a 9-s window of raw data. After QRS and
-wave detection, a seed beat was automatically detected
ased on its matching with all other beats in the 9-s win-
ow of raw data. A template matching with the selected
eed beat was performed within these data. All P-waves that
et the criteria of P-wave matching were then averaged for
template.
In the averaging phase, QRS detection was performed
rst, and then QRS-T portion was subtracted. P-waves were
etected in a window ranging from previous T-wave offset
o the current QRS onset points from a composite abso-
ute value of band-pass ﬁltered and ﬁrst-differenced X, Y,
nd Z signals. Qualiﬁed P-waves with accepted P duration
nd correlation coefﬁcient >0.95 were averaged. The aver-
ging process continued until either the target number of
eats (250—400) or the desired noise level of <0.3V was
chieved.
The averaged P-wave signals were ﬁltered by a spec-
ral band-pass ﬁlter with a bandwidth of 40—250Hz, and
hen combined into a vector magnitude using the formula
X2 +Y2 + Z2)1/2. The P-wave delineation was performed on
he vector magnitude. The P-SAECG measurements included
ltered P-wave duration (P-dur) and the voltage of the root
ean square (RMS) in microvolts (Fig. 2). The RMS voltage is
he RMS of the spatial magnitude over an interval. We mea-
210
F
w
m
s
s
S
R
u
b
u
p
w
v
R
C
T
T
f
t
C
a
T
t
r
a
t
g
c
s
a
s
g
t
g
s
n
C
a
T
t
e
d
(
i
t
c
a
s
b
T
h
i
r
m
C
treatmentigure 2 Signal-averaged electrocardiogram triggered by P
aves. (a) Filtered P-wave duration. (b) The voltage of the root
ean square.
ured the RMS voltage for 30ms of the ﬁltered P-wave of the
patial magnitude and its duration.
tatistical analysis
esults are expressed as the mean± SD. Continuous val-
es were compared with analysis of variance. Comparison
etween two groups at each time was performed using
npaired t test. Comparison within the groups at each
oint was performed using paired t test. Categorical data
ere compared against a chi-squared distribution. A p-
alue < 0.05 was regarded as signiﬁcant.
esults
linical characteristicsable 1 shows the clinical characteristics before treatment.
here were no differences in age, gender, etiology of heart
ailure, LVEF, or medications on entry into the study between
he spironolactone group and the control group.
F
T
b
Table 1 Clinical characteristics.
Control group
Age (years) 68± 7
Gender (men/women) 7/3
Etiology (ICM/DCM) 7/3
LVEF (%) 36± 6
ACEI (%) 60
ARB (%) 40
 blocker (%) 80
Antiarrhythmic drug (%) 20
ICM, ischemic cardiomyopathy; DCM, dilated cardiomyopathy; LVEF,
enzyme inhibitor; ARB, angiotensin receptor blocker.M. Kimura et al.
omparison of neurohumoral factors before and
fter treatment
able 2 shows neurohumoral factors before and after
reatment. There were no differences in pretreatment neu-
ohumoral factors, such as ALD, plasma renin activity (PRA),
trial natriuretic peptide (ANP), and brain natriuretic pep-
ide (BNP) between the spironolactone group and the control
roup. In the control group, there were no signiﬁcant
hanges in these variables after 3 and 12 months. In the
pironolactone group, ALD and PRA signiﬁcantly increased,
nd ANP and BNP tended to reduce after treatment. The
erum potassium concentration did not change in the control
roup during 12 months. During the same period, however,
he serum potassium concentration in the spironolactone
roup increased by 0.5mmol per liter. The difference in the
erum potassium concentration between the two groups was
ot signiﬁcant and was not clinically important.
omparison of echocardiographic variables before
nd after treatment
able 3 shows echocardiographic variables before and after
reatment. There were no differences of pretreatment
chocardiographic variables, such as left ventricular end-
iastolic dimension (LVEDd), LVEF, left atrium dimension
LAd), and peak velocities of early (E) and late (A) mitral
nﬂow between the spironolactone group and the con-
rol group. In the control group, there were no signiﬁcant
hanges in LVEDd and LAd after treatment. However, LVEDd
nd LAd in the spironolactone group were signiﬁcantly
maller after 12 months. The differences in LVEDd and LAd
etween the two groups after 12 months were signiﬁcant.
he LVEF in the control group signiﬁcantly became worse,
owever, the LVEF in the spironolactone group tended to
mprove after 12 months. Furthermore, the A wave and the
atio of E wave to A wave (E/A) tended to improve after 12
onths in the spironolactone group.
omparison of P-SAECG variables before and afterig. 3 shows P-SAECG variables before and after treatment.
here were no differences of pretreatment P-dur and RMS
etween the spironolactone group and the control group. In
Spironolactone group
67± 8 N.S.
8/3 N.S.
7/4 N.S.
34± 6 N.S.
55 N.S.
45 N.S.
82 N.S.
18 N.S.
left ventricular ejection fraction; ACEI, angiotensin-converting
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Table 2 Neurohumoral factors before and after treatment.
Study enrollment 3 months 12 months
Aldosterone (ng/dl)
Control 5.8 ± 1.1 5.5 ± 0.9 6.3 ± 1.1
Spironolactone 7.2 ± 1.9 13.5 ± 2.6#,$ 14.8 ± 3.2#,$
PRA (ng/ml/h)
Control 2.4 ± 0.4 2.5 ± 0.3 4.4 ± 1.9
Spironolactone 4.4 ± 1.9 13.2 ± 4.1#,$ 13.1 ± 4.8#,$
ANP (pg/ml)
Control 45 ± 11 44 ± 10 50 ± 10
Spironolactone 77 ± 38 55 ± 27 48 ± 17
BNP (pg/ml)
Control 120 ± 27 121 ± 27 156 ± 36
Spironolactone 128 ± 36 107 ± 33 95 ± 29
K (mEq/l)
Control 4.2 ± 0.2 4.1 ± 0.2 4.3 ± 0.2
Spironolactone 4.0 ± 0.2 4.3 ± 3.1# 4.5 ± 0.2#
Hematocrit (%)
Control 42 ± 5 40 ± 5# 40 ± 4
Spironolactone 39 ± 5 41 ± 5# 39 ± 4
rain n
DPRA, plasma renin activity; ANP, atrial natriuretic peptide; BNP, b
# p < 0.05 (comparison within the groups at each point).
$ p < 0.05 (comparison between the two groups at each time).
the control group, there were no signiﬁcant changes in P-
dur and RMS after 3 months. However, in the spironolactone
group, P-dur was signiﬁcantly shortened and RMS was signif-
icantly higher after 3 months. The differences in P-dur and
RMS between the two groups were signiﬁcant and continued
at least during 12 months.
T
a
T
E
Table 3 Echocardiographic variables before and after treatment
Study enrollment
LVEDd (mm)
Control 57 ± 6
Spironolactone 61 ± 4
LVEF (%)
Control 36 ± 6
Spironolactone 34 ± 6
LAd (mm)
Control 40 ± 6
Spironolactone 42 ± 3
A (cm/s)
Control 72 ± 14
Spironolactone 65 ± 21
E/A
Control 0.9 ± 0.2
Spironolactone 1.4 ± 0.4
IVC (mm)
Control 12 ± 2
Spironolactone 13 ± 3
LVEDd, left ventricular end-diastolic dimension; LVEF, left ventricular
of early mitral inﬂow; A, peak velocities of late mitral inﬂow; IVC, infe
# p < 0.05 (comparison within the groups at each point).
$ p < 0.05 (comparison between the two groups at each time).atriuretic peptide.
iscussionhis study has demonstrated that spironolactone improves
trial conduction and remodeling in patients with HF.
he major ﬁndings of this study were that ANP and
/A tended to reduce, LAd was signiﬁcantly smaller, and
.
3 months 12 months
58 ± 6 59 ± 7#
59 ± 5# 57 ± 5#
35 ± 5 33 ± 7#
34 ± 6 37 ± 8
40 ± 7 43 ± 7
40 ± 4 37 ± 3#,$
69 ± 18 69 ± 14
70 ± 19 72 ± 16
0.9 ± 0.2 0.9 ± 0.3
0.8 ± 0.3 0.7 ± 0.3
12 ± 2 13 ± 4
11 ± 2# 12 ± 2
ejection fraction; Lad, left atrium dimension; E, peak velocities
rior vena cava dimension.
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Figure 3 Comparison of P-SAECG variables before and after treatment. In the spironolactone group, ﬁltered P-wave duration (A)
was signiﬁcantly shortened and the voltage of the root mean square (B) was signiﬁcantly higher after 3 months. The differences in
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uring 12 months. P-SAECG, signal-averaged electrocardiogram
ircles = spironolactone group; triangles = control group.
-dur was signiﬁcantly shortened in the spironolactone
roup.
echanisms
everal possible mechanisms exist by which spironolac-
one may improve atrial conduction and remodeling. These
nclude decrease of wall stress, modulation of refrac-
oriness, interference with ion currents, modiﬁcation of
ympathetic tone, and stabilization of electrolyte concen-
rations [18—23].
trial stretch and spironolactone
e have no data to explain the underlying mechanism of
he ﬁnding in our study. However, increasing evidence sug-
ests that atrial stretch induced by increased atrial pressure
ay precipitate AF through an effect on atrial refractori-
ess [23,24]. Bauersachs et al. showed that the addition of
pironolactone to ACE inhibition in HF signiﬁcantly increased
rinary sodium and volume excretion, leading to reduced
lling pressures [25]. Our data conform to the hypothesis
hat the reduction of intravascular volume (as suggested by
he reduction of inferior vena cava dimension and increase
f hematocrit) by spironolactone may reﬂect the diuretic
ction of spironolactone. Furthermore, reduced plasma lev-
ls of ANP in patients with HF treated with spironolactone
ay indicate a reduced preload, leading to improve atrial
tretch in the present study.
trial remodeling and spironolactoneeveral studies have shown a positive correlation between
trial enlargement and the incidence of AF [26—29].
etersen et al. compared the left atrial size, as determined
y echocardiography, in patients in sinus rhythm with that
f patients with AF [26]. The atria in sinus rhythm were
a
m
t
m
tetween the two groups were signiﬁcant and continued at least
ered by P waves. Error bars represent 95% conﬁdence intervals.
maller than that of patients with AF. For many years, it
as been discussed whether atrial enlargement is the cause
r a consequence of AF. However, the high incidence of AF in
he presence of mitral stenosis and/or mitral insufﬁciency
trongly suggests atrial dilatation to be a cause of AF [27,28].
n the present study, LAd in the spironolactone group was
igniﬁcantly smaller after 12 months. Furthermore, spirono-
actone prevents myocardial ﬁbrosis by blocking the effects
f ALD on the formation of collagen. It may be a cause
f improvement of RMS in the spironolactone group in the
resent study.
trial conduction and spironolactone
F is multifactorial, one of the suggested mechanisms being
ultiple microreentry. By deﬁnition of reentry, depressed
onduction is required for the occurrence of AF [30,31].
t was reported that the atrial conduction abnormalities in
atients with lone paroxysmal AF (PAF) could be detected
y SAECG P-wave, and this could be utilized as a noninva-
ive method for detection of patients at risk for lone PAF
32]. In addition, studies showed that prolonged ﬁltered P-
ave duration in sinus rhythm is considered to indicate an
ncreased risk for PAF in patients with and without structural
eart disease [33—35].
HF is not only associated with severe structural and
unctional changes of the atria, but also related to electro-
hysiologic abnormalities. Hemodynamic atrial changes may
ause depressed atrial conduction, fragmented atrial activ-
ty, and multiple atrial stimulation foci that could predispose
o AF [36]. Depressed atrial conduction prolongs atrial acti-
ation time and that prolongs P wave. Fragmented atrial
ctivity causes low amplitude late potentials on the ter-
inal portion of the P wave. P-wave signal-averaged ECG
echnique can detect the duration and the terminal seg-
ent amplitude of the P wave. Therefore, with the P-SAECG
echnique, PAF risk can be detected.
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Experimental studies have shown that acute atrial stretch
prolongs the conduction time and increases spatial hetero-
geneities in conduction [37,38]. In a canine model of HF,
interstitial ﬁbrosis and heterogeneous conduction were con-
sidered important determinants of the substrate for AF [39].
In human studies as well, atrial dilatation and impaired con-
duction were correlated with atrial arrhythmias [40—42]. A
reduced conduction velocity shortens the wavelength and
thereby could stabilize AF. In our present study, the reduc-
tion of atrial stretch and the inhibition of atrial remodeling
by spironolactone were associated with the improvement of
atrial conduction, leading to improve P-dur and RMS.
Clinical implications
Increased interest in and the use of spironolactone have
resulted from clinical trials demonstrating decreased mor-
tality in patients with HF treated with spironolactone. The
current study offers important new mechanistic insights into
the effects of spironolactone in HF, providing novel informa-
tion about its role in modulation of atrial electrophysiology
and left ventricular function. AF is common in patients
with HF and associated with increased morbidity and mor-
tality, but their treatment remains less than optimal. Our
data open an entirely new potential and promising role
for spironolactone in the prevention of AF in patients with
HF. Furthermore, PRA and ALD levels began to increase by
treatment with spironolactone, suggesting blockade of ALD
receptors and positive neurohormonal feedback. Therefore,
combination therapy with ACE inhibition is very important.
However, the problem of hyperkalemia is also important in
patients treated with combination therapy. Previous stud-
ies suggested that combination therapy began at a dose of
25mg/day of spironolactone. In the present study, at a dose
of 25mg of spironolactone, the serum potassium concentra-
tion in the spironolactone group increased by 0.5mmol per
liter, but it was not clinically important.
Limitations
The primary limitation of this study is the small study pop-
ulation of only 21 patients. Without the power estimation
and due to the low number of patients included, the study
must be regarded as a pilot study. Therefore, further stud-
ies are needed to assess the effects of spironolactone in
patients with HF. In addition, the present study employed
a ﬁxed spironolactone dose of 25mg/day, therefore, the
dose—response effect of spironolactone on atrial conduction
and remodeling must also be evaluated.
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